524494 Stock Overview
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 524494 from our risk checks.
Ipca Laboratories Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹1,238.25 |
52 Week High | ₹1,264.00 |
52 Week Low | ₹670.00 |
Beta | 0.23 |
1 Month Change | 3.69% |
3 Month Change | 11.22% |
1 Year Change | 57.45% |
3 Year Change | 31.48% |
5 Year Change | 158.04% |
Change since IPO | 1,497.74% |
Recent News & Updates
Recent updates
Shareholder Returns
524494 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 5.5% | 2.7% | 2.5% |
1Y | 57.4% | 63.9% | 47.3% |
Return vs Industry: 524494 underperformed the Indian Pharmaceuticals industry which returned 63.9% over the past year.
Return vs Market: 524494 exceeded the Indian Market which returned 47.3% over the past year.
Price Volatility
524494 volatility | |
---|---|
524494 Average Weekly Movement | 4.4% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in IN Market | 10.1% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 524494 has not had significant price volatility in the past 3 months.
Volatility Over Time: 524494's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1949 | 16,167 | Pranay Godha | https://www.ipca.com |
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives.
Ipca Laboratories Limited Fundamentals Summary
524494 fundamental statistics | |
---|---|
Market cap | ₹305.79b |
Earnings (TTM) | ₹5.64b |
Revenue (TTM) | ₹71.87b |
55.6x
P/E Ratio4.4x
P/S RatioIs 524494 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
524494 income statement (TTM) | |
---|---|
Revenue | ₹71.87b |
Cost of Revenue | ₹26.97b |
Gross Profit | ₹44.90b |
Other Expenses | ₹39.26b |
Earnings | ₹5.64b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 22.24 |
Gross Margin | 62.47% |
Net Profit Margin | 7.85% |
Debt/Equity Ratio | 26.3% |
How did 524494 perform over the long term?
See historical performance and comparison